Primary Site >> Biliary tract Cancer

Gene >> AKT2

Journal: J Hepatol. 2009 Jul;51(1):93-101.
Title: Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas.
Author: Guedj, Nathalie|Zhan, Qian|Perigny, Martine|Rautou, Pierre-Emmanuel|Degos, Francoise|Belghiti, Jacques|Farges, Olivier|Bedossa, Pierre|Paradis, Valerie
PMID: 19446907
Journal: Int J Cancer. 2013 Nov;133(9):2065-76.
Title: Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Author: Ewald, Florian|Grabinski, Nicole|Grottke, Astrid|Windhorst, Sabine|Norz, Dominik|Carstensen, Lisa|Staufer, Katharina|Hofmann, Bianca T|Diehl, Frank|David, Kerstin|Schumacher, Udo|Nashan, Bjorn|Jucker, Manfred
PMID: 23588885
Journal: Tumour Biol. 2016 Jul;37(7):9721-30.
Title: Long noncoding RNA H19 contributes to gallbladder cancer cell proliferation by modulated miR-194-5p targeting AKT2.
Author: Wang, Shou-Hua|Wu, Xiao-Cai|Zhang, Ming-Di|Weng, Ming-Zhe|Zhou, Di|Quan, Zhi-Wei
PMID: 26803515
Journal: Oncotarget. 2017 Jan 17;8(3):5349-5360.
Title: Guidance to rational use of pharmaceuticals in gallbladder sarcomatoid carcinoma using patient-derived cancer cells and whole exome sequencing.
Author: Feng, Feiling|Cheng, Qingbao|Yang, Liang|Zhang, Dadong|Ji, Shunlong|Zhang, Qiangzu|Lin, Yihui|Li, Fugen|Xiong, Lei|Liu, Chen|Jiang, Xiaoqing
PMID: 28029662